Study Evaluating Temsirolimus (CCI-779) In Breast Neoplasms
Status:
Completed
Trial end date:
2009-10-01
Target enrollment:
Participant gender:
Summary
To evaluate the preliminary activity and pharmacokinetics of 2 separate doses and schedules
of orally administered Temsirolimus (CCI-779) given in combination with daily letrozole,
compared to letrozole alone, in the treatment of locally advanced or metastatic breast cancer
in postmenopausal women. All patients must be appropriate to receive endocrine therapy as
treatment for advanced disease.